DrugDashboards

Baxfendy

baxdrostat · BAXDROSTAT 1 mg/1 · Tablet, Film Coated · Oral · AstraZeneca Pharmaceuticals LP

NDC 00310-6001-30 · 30 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Regulatory

Application
NDA219878
TE code
Approval date
May 15, 2026
Patents / exclusivity
2 patents, 2 exclusivities
TypeNumber / codeExpires
exclusivityNCEMay 15, 2031
exclusivityNCEMay 15, 2031
patent9353081Feb 4, 2033
patent9353081Feb 4, 2033

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of baxdrostat (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
AstraZeneca ABBAXDROSTAT 1 mg/1Jul 15, 2026Sep 2, 2026
AstraZeneca ABBAXDROSTAT 2 mg/1Jul 15, 2026Sep 2, 2026
AstraZeneca Pharmaceuticals LPBAXDROSTAT 1 mg/1Jul 15, 2026Sep 2, 2026
AstraZeneca Pharmaceuticals LPBAXDROSTAT 2 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Baxfendy — NDC 00310-6001-30," retrieved September 3, 2026, https://drugdashboards.com/drug/00310600130.

Free to cite with attribution — see how the data is put together.